Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma

Detalles Bibliográficos
Autores principales: Lara, Kristi M., In, Gino K., Matcuk, George R., Mehta, Arjun, Hu, James S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226586/
https://www.ncbi.nlm.nih.gov/pubmed/30450405
http://dx.doi.org/10.1016/j.jdcr.2018.10.003
_version_ 1783369975896997888
author Lara, Kristi M.
In, Gino K.
Matcuk, George R.
Mehta, Arjun
Hu, James S.
author_facet Lara, Kristi M.
In, Gino K.
Matcuk, George R.
Mehta, Arjun
Hu, James S.
author_sort Lara, Kristi M.
collection PubMed
description
format Online
Article
Text
id pubmed-6226586
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-62265862018-11-16 Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma Lara, Kristi M. In, Gino K. Matcuk, George R. Mehta, Arjun Hu, James S. JAAD Case Rep Case Report Elsevier 2018-11-07 /pmc/articles/PMC6226586/ /pubmed/30450405 http://dx.doi.org/10.1016/j.jdcr.2018.10.003 Text en © 2018 Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Lara, Kristi M.
In, Gino K.
Matcuk, George R.
Mehta, Arjun
Hu, James S.
Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma
title Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma
title_full Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma
title_fullStr Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma
title_full_unstemmed Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma
title_short Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma
title_sort talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory merkel cell carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226586/
https://www.ncbi.nlm.nih.gov/pubmed/30450405
http://dx.doi.org/10.1016/j.jdcr.2018.10.003
work_keys_str_mv AT larakristim talimogenelaherparepvecincombinationwithpembrolizumableadstoacompleteresponseinapatientwithrefractorymerkelcellcarcinoma
AT inginok talimogenelaherparepvecincombinationwithpembrolizumableadstoacompleteresponseinapatientwithrefractorymerkelcellcarcinoma
AT matcukgeorger talimogenelaherparepvecincombinationwithpembrolizumableadstoacompleteresponseinapatientwithrefractorymerkelcellcarcinoma
AT mehtaarjun talimogenelaherparepvecincombinationwithpembrolizumableadstoacompleteresponseinapatientwithrefractorymerkelcellcarcinoma
AT hujamess talimogenelaherparepvecincombinationwithpembrolizumableadstoacompleteresponseinapatientwithrefractorymerkelcellcarcinoma

Ejemplares similares